Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1 6Phase 1/2 2

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 17Gynecologic 6CNS 5Sarcoma 3Thoracic 2Head & Neck 2Genitourinary 2Gastrointestinal 2Tumor-Agnostic 1Plasma cell 1Other solid neoplasm 1

Conditions

Colorectal Neoplasms 2Rectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Gemcitabine 153Oxaliplatin 124Fluorouracil 108Capecitabine 105pembrolizumab 92Bevacizumab 81Leucovorin 75Irinotecan 72Nivolumab 70130-nm albumin-bound paclitaxel 68Paclitaxel 62Cisplatin 62Cetuximab 60Cyclophosphamide 46Albumin-Bound Paclitaxel 45Radiotherapy 39Docetaxel 36durvalumab 33Sorafenib 32Taxes 29Carboplatin 27tislelizumab 25fludarabine 25Drug Therapy 25atezolizumab 24Folfox protocol 23regorafenib 20lenvatinib 19Ipilimumab 19sintilimab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × abemaciclib × Gastrointestinal × Clear all
NCT04616183 2025-12-23

LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
46 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT04165031 2021-11-24

A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation

Eli Lilly and Company

Phase 1/2 Terminated
5 enrolled 9 charts
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡